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INTRODUCTION
Cyclooxygenase (COX) is a bifunctional enzyme with cy-
clooxygenase and peroxidase activities. The cyclooxygenase
activity of COX is important for the initial conversion of
arachidonic acid to prostaglandin (PG) G2, and the peroxi-
dase activity of COX then converts it to PG H2. Finally, PG
H2 is converted to other PGs by a variety of tissue specific
enzymes. These PGs then exert their biologic actions on these
tissues (1, 2). There are two isoforms of COX, a constitutive
isoform COX-1 and an inducible isoform COX-2. COX-1
is constitutively expressed to fulfill its beneficial housekeep-
ing roles. In contrast, COX-2 is frequently undetectable at
baseline in most normal tissues, but it is rapidly induced by
cytokines, tumor promoters, growth factors and carcinogens
(3-5). Increased COX-2 expression has been demonstrated
in various human cancers including gastric cancer and has
been implicated in carcinogenesis (6-8). Furthermore, selec-
tive COX-2 inhibitors have been shown to have antineoplas-
tic activities in various cancers (9, 10).
The several mechanisms by which COX-2 may contribute
to carcinogenesis are beginning to unravel. These include that
COX-2 stimulates tumor cell proliferation, inhibits apopto-
sis, increases the invasiveness of malignant cells, and enhance
angiogenesis through the production of angiogenic factors
(11-14). We previously reported that COX-2 may play a crit-
ical role in carcinogenesis by stimulating tumor angiogenesis
in concert with vascular endothelial growth factor (VEGF)
in human gastric cancer (15).
Regarding tumor cell proliferation, it is widely accepted
that proliferative capacity may influence the clinical course,
and hence patient prognosis. Ki-67, a nuclear antigen is ex-
pressed in all stages of the cell cycle except G0 and early G1,
and it is often used to indicate the proliferative activity of
tumors (16). 
Tumor development, growth and progression are charac-
terized by uncontrolled cell proliferation. This is usually the
result of multiple genetic and epigenetic insults to the cell,
particularily involving oncogenes and tumor suppressor genes
(17). The p53, tumor suppressor gene is one of the most fre-
quently mutated genes in human cancers. The p53 tumor
suppressor gene is believed to play a pivotal role in prevent-
ing the uncontrolled cell proliferation characteristic of can-
cer. Recent studies reported that mutation of p53 may con-
tribute to the increased COX-2 expression that is observed
in malignant tissues (18, 19).
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Expression of Cyclooxygenase-2, p53 and Ki-67 in Gastric Cancer
It has been reported that p53 mutation may contribute to upregulate cyclooxyge-
nase (COX)-2 expression that is observed in malignant tissues. These molecules
are involved in carcinogenesis by affecting tumor cell proliferation. The aim of this
study was to examine the relationship between COX-2 or p53 expression and clinico-
pathological characteristics including tumor cell proliferation in gastric cancer. COX-2
and p53 expressions were investigated with immunostaining, in tissue specimens
obtained from 119 patients who underwent surgery for gastric cancer. The Ki-67 label-
ing index (LI) was counted by Ki-67 immunostaining. COX-2 and p53 expressions
correlated significantly with depth of tumor invasion. However, there was no asso-
ciation between COX-2 or p53 expression and survival. p53 expression did not cor-
relate with COX-2 expression. There was no significant difference in various clini-
copathological variables between Ki-67 LI subgroups. The mean Ki-67 LI value of
COX-2 positive tumors was significantly higher than that of negative tumors. The
mean Ki-67 LI value of p53 positive tumors was not significantly higher than that of
negative tumors. The mean Ki-67 LI value of both COX-2 and p53 positive tumors
was significantly higher than that of both negative tumors. These results imply that
COX-2 expression is associated with tumor cell proliferation of gastric cancer. 
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However, the role of increased COX-2 expression and p53
mutation in gastric cancer cell proliferation has not been fully
established. The aim of this study was to evaluate the expres-
sion of COX-2 and p53 in gastric cancer and to examine the
relationship between their expression and various clinicopa-
thological characteristics including tumor cell proliferation.
MATERIALS AND METHODS
Sample selection
This study was based on an analysis of formalin-fixed, paraf-
fin-embedded tissue specimens obtained from 119 patients
who had gastric cancer and who underwent surgical resection
at Chonnam National University Hospital from July 1994
to June 1995. None of the patients had received preoperative
irradiation or chemotherapy before undergoing surgery. The
specimens were taken from representative cancerous lesions
over their greatest length and included adjacent noncancer-
ous areas. Clinicopathological characteristics and survival data
were obtained by hospital records, pathologist and physician
contact when necessary. The tumors were staged at the time
of surgery by the standard criteria for TNM staging using the
American Joint Committee on Cancer (AJCC) (20). The mean
age was 58.7±10.9 yr (mean±SD) with a range from 28 to
79 yr. Eighty-four patients were male, and 35 were female.
The mean size of tumor was 5.1±2.7 cm (mean±SD) with
a range from 0.5 to 15.0 cm. The mean follow-up period was
65.4 months with a range from 1.3 to 119.8 months
Immunohistochemistry
All procedures for immunohistochemical staining were
done by the Micro-Probe staining system (Fisher Scientific,
Pittsburgh, PA, U.S.A.) based on capillary action (21). Forma-
lin-fixed, paraffin-embedded tissue blocks were cut to 4- m-
thick sections for immunohistochemical staining. A standard
avidin-biotin peroxidase complex method was used. Sections
were deparaffinized using xylene and transferred to alcohol.
Endogenous peroxidase activity was blocked using the 0.6%
hydrogen peroxide and incubated for 5 min. Antigen retrieval
was performed by microwave for 7 min. A monoclonal mouse
immunoglobulin antibody to COX-2 (160112; diluted 1:
250; Cayman Chemical Co, Ann Arbor, MI, U.S.A.), p53
(DO-7; diluted 1:100; Dakopatts, Glostrup, Denmark), and
Ki-67 (MIB-1; diluted 1:150; Dakopatts, Glostrup, Denmark)
were used as primary antibodies. The primary antibodies, in
the aforementioned concentrations were diluted in phosphate-
buffered saline supplemented with 5% normal horse serum
and 1% bovine serum albumin and then incubated with tis-
sues for 25, 15 min at 45℃, and 90 min at room tempera-
ture, respectively for COX-2, p53 and Ki-67. Anti-mouse
immunoglobulin G (Sigma, St. Louis, MO, U.S.A.) labeled
with biotin was used as a secondary antibody for the detec-
tion of primary antibodies and slides were incubated for 10
min at 45℃. After multiple rinses with universal buffer, the
slides were incubated in streptavidin-horseradish peroxidase
solution (Biomeda, Foster, CA, U.S.A.) for 10 min. As the
final step, the slides were developed for 10 min with the en-
zyme substrate, 3 amino-9-ethyl carbazole (AEC, Sigma, St.
Louis, MO, U.S.A.). The slides were then counterstained with
hematoxylin solution for 1 min (Research Genetics, Hunts-
ville, AL, U.S.A.). After dehydration, the tissue was sealed
with a universal mount (Research Genetics). For negative con-
trols, the primary antibody was omitted and replaced with
phosphate-buffered saline.
Interpretation of immunohistochemical stains for COX-2,
p53 and Ki-67
The immunohistochemical staining was evaluated inde-
pendently by two pathologists without knowledge of the clin-
ical outcomes, analysing the intensity, area and pattern of im-
munohistochemical staining. In case of disagreement, the
slides were reviewed and a consensus view achieved. COX-2
immunoreactivity score was calculated as the product of stain-
ing intensity and staining area. The staining intensity was
arbitrarily graded on a scale of four grades: 0, no staining of
cancer cells; 1, weak staining; 2, moderate staining; 3, strong
staining. The percentage of staining area was also graded on
a scale with four grades: 0, none; 1, <10%; 2, 10-50%; 3, >50
%. Theoretically, the overall scores could range from 0 to 9.
The specimens with a score of more than 4 were regarded as
positive expression, and those with a score ≤4 as negative
expression. p53 immunoreactivity was assessed as being posi-
tive only when tumors exhibited intense nuclear staining, and
immunoreactivity was categorized into 2 groups: negative
expression (less than 10% positive tumor cells) and positive
expression (at least 10% positive tumor cells). A distinct nu-
clear immunoreactivity for Ki-67 was considered positive. The
Ki-67 labeling index (LI) was determined by observing 1000
cancer cell nuclei in areas of the section with highst labeling
frequency, and the percentage of Ki-67-labeled nuclei was
used for analysis (16).
Statistical analysis
The  2-test and Fisher’s exact test, where appropriate, were
used to compare expression of the COX-2, p53 and Ki-67 LI
subgroups with various clinicopathological variables. The cor-
relation between COX-2 or p53 expression and Ki-67 LI was
analyzed for statistical significance using Student’s t test. Actu-
arial survival rates of patients were evaluated according to the
Kaplan-Meier method and the differences were tested with
a log-rank test. The statistical software program used was Sta-
tistical Package for the Social Sciences (SPSS/PC+12.0, Chi-
cago, IL, U.S.A.). The value of significance was taken as p<0.05.COX-2, p53 and Ki-67 Expression in Gastric Cancer 873
RESULTS
Expression of COX-2, p53, and Ki-67 in gastric cancer
COX-2 immunoreactivity was cytoplasmic and was almost
exclusively restricted to cancerous areas of pathologic specimens
(Fig. 1). In some tumors, the COX-2 staining was diffuse,
and in other tumors it was localized. In the normal gastric
epithelia of non-cancerous area, no COX-2 immunoreactivity
was observed. Immunoreactivity specific for p53 protein was
evident in the nuclei of cancer cells and heterogenously dis-
tributed. Ki-67 immunoreactivity was almost found in the
nuclei of cancer cells. Positive cells were frequent in the advanc-
ing margin of the tumor. Based on our criteria, expression
of COX-2 and p53 in gastric cancer tissues, was demonstrat-
ed in 60.5% (72/119) and 34.5% (41/119), respectively. 
Correlation between COX-2 or p53 expression and clini-
copathological variables
The correlation between COX-2 or p53 expression and clini-
copathological variables is shown in Table 1. Expression of
COX-2 and p53 correlated significantly with depth of tumor
invasion (p=0.005, 0.036 respectively). However, there was
Fig. 1. Immunoreactivity of COX-2 in gastric cancer tissues. COX-
2 immunoreactivity is predominantly detected in the cytoplasm of
cancer cells (×200). 
Clinicopathological 
variables
Total
(n=119)
COX-2
- (n=47) + (n=72) p
p53
- (n=78) + (n=41) p
Ki-67 LI
Low 
(n=57)
High 
(n=62)
p
Age (yr)
<59 52 22 30 0.580 32 20 0.418 30 22 0.060
≥59 67 25 42 46 21 27 40
Sex
Male 84 33 51 0.942 53 31 0.383 38 46 0.368
Female 35 14 21 25 10 19 16
Tumor size (cm)
<5.1 cm 74 28 46 0.635 46 28 0.319 35 39 0.866
≥5.1 cm 45 19 26 32 13 22 23
Depth of invasion
T1 16 12 4 0.005 13 3 0.036 7 9 0.510
T2 29 7 22 13 16 17 12
T3 61 25 36 44 17 26 35
T4 13 3 10 8 5 7 6
Lymph node metastasis 
N0 58 25 33 0.432 39 19 0.704 26 32 0.513
N1-3 61 22 39 39 22 31 30
Distant metastasis
M0 101 42 59 0.270 64 37 0.236 47 54 0.480
M1 18 5 13 14 4 10 8
TNM stage
I 41 18 23 0.856 26 15 0.355 21 20 0.766
II 19 8 11 14 5 8 11
III 37 13 24 21 16 16 21
IV 22 8 14 17 5 12 10
Table 1. Correlation between COX-2, p53 expression and Ki-67 labeling index (LI) and clinicopathological variables of gastric cancers
-, Negative; +, Positive; COX-2, Cyclooxygenase-2.no association between COX-2 or p53 expression and tumor
stage, status of lymph node, or distant metastasis. Further-
more, COX-2 and p53 expression did not associate with pati-
ent survival (p=0.927, 0.336 respectively) (Fig. 2A, B). The
expression of p53 did not correlate with COX-2 expression
(p=0.939) (Table 2). 
Correlation between Ki-67 LI and clinicopathological vari-
ables
The Ki-67 LI for 119 tumors ranged from 7.6% to 85.8%
with a mean Ki-67 LI of 49.5±15.5. When a mean Ki-67
LI value of 49.5 was chosen as the cut-off point for discrimi-
nation of the 119 patients into two subgroups, 57 patients
were categorized as high Ki-67 LI and 62 as low Ki-67 LI.
There was no significant difference in various clinicopatholo-
gical variables including survival between the two subgroups
(Table 1) (Fig. 2C).
Correlation between COX-2 or p53 expression and Ki-67
LI
The correlation between COX-2 or p53 expression and
Ki-67 LI is shown in Table 3. The mean Ki-67 LI value of
COX-2 positive tumors was 52.3±14.6 and significantly
higher than that of COX-2 negative tumors (p=0.012). The
mean Ki-67 LI value of p53 positive tumors was 50.7±14.7
and not significantly higher than that of p53 negative tumors
(p=0.525). Combined analysis of COX-2 and p53 status show-
ed that the mean Ki-67 LI value of both positive tumors was
significantly higher than that of both negative tumors (p=
0.025).
DISCUSSION
Most of antineoplastic effects of aspirin and other non-ste-
roidal anti-inflammatory drugs have been linked to their abi-
lity to suppress PGs synthesis through inhibition of the activi-
ty of the inducible isoform COX-2 (9, 10). Overproduction
of COX-2 and PGs has been found to accompany the devel-
opment and progression of various human cancers including
gastric cancer (6-8). However, the precise mechanisms by
which they act is not yet understood. Therefore, understand-
ing of underlying mechanisms of COX-2 action in cancer
development and progression may lead to a better understand-
ing of carcinogenesis. Recent studies have shown that COX-2
and PGs promote carcinogenesis as well as growth and spread
of established tumors by stimulating cell proliferation, inhibi-
ting apoptosis, increasing the invasiveness of malignant cells,
and enhancing the production of VEGF, which promotes an-
giogenesis (11-14). 
Ki-67 is recognized as a nuclear antigen present in prolif-
erating cells but absent in resting quiescent cells. The Ki-67
LI, determined by Ki-67 immunohistochemistry, is a well-
known proliferation marker and has been extensively used to
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Fig. 2. Kaplan-Meier survival curve correlating disease specific survival with positive (solid line) or negative (dotted line) expression of COX-
2 (A), p53 (B), and high (solid line) or low (dotted line) Ki-67 LI (C).
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COX-2 expression p-value
p53 expression
Positive (n=41) Negative (n=78)
Positive (n=72) 25 47
Negative (n=47) 16 31 0.939
Table 2. Correlation between COX-2 and p53 expression in gas-
tric cancer
COX-2/p53 status p-value
Total
(n=119)
Ki-67 LI
Mean±SD (%)
COX-2
Negative 47 45.1±16.0 0.012
Positive 72 52.3±14.6
p53
Negative 78 48.8±16.0 0.525
Positive 41 50.7±14.7
COX-2/p53
Positive/Positive* 25 54.5±13.0 0.025*
Positive/Negative 47 51.2±15.4
Negative/Positive 16 44.8±15.7
Negative/Negative* 31 45.3±16.4
Table 3. Correlation between Ki-67 labeling index (LI) and sta-
tus of COX-2 and p53 in gastric cancer
SD, Standard deviation; COX-2, Cyclooxygenase-2; *Student’s t test.estimate the growth fraction of tumors (16). 
This study is the first to document the possible role of COX-
2 expression for tumor cell proliferation in gastric cancer. In
this study, the mean Ki-67 LI value of COX-2 positive tumors
was significantly higher than that of COX-2 negative tumors.
This result was concordant with result obtained by Yama-
gishi et al. (22). Also, Sawaoka et al. reported that both selec-
tive and non-selective COX-2 inhibitors exerted minimal
effects on cell proliferation of human gastric cancer cell lines,
which expressed lower levels of COX-2, but suppressed cell
proliferation of human gastric cancer cell lines that overex-
pressed COX-2 (23). These results imply that COX-2 play
a critical role in tumor cell proliferation of gastric cancer. 
It is known that wild type p53, but not mutant p53, sup-
presses a variety of promoters that contain TATA elements
(24). A recent in vitro study demonstrated that wild type
p53 inhibits the formation of the complex between TATA
binding protein and the promoter region of COX-2 gene in
a cell-free system (18). Therefore, mutation of p53 may con-
tribute to upregulate COX-2 expression, and it may be in-
volved in the regulation of tumor cell proliferation.
The second aim of this study was to evaluate the correlation
between p53 and COX-2 expression, with special reference
to tumor cell proliferation. In this study, the expression of
p53 did not correlate with COX-2 expression. In contrast,
previous studies reported that tumors with p53 mutation were
associated with higher level of COX-2 expression (18, 19).
There are some possible explanations for this discrepancy. First,
induction of COX-2 is not dependent on mutation of p53
alone, and regulated by many factors including cytokines,
tumor promoters, growth factors, and oncogenes (3-5). Sec-
ond, the mutant p53 protein is frequently more stable than
wild type, and this stabilized protein product can therefore
be detected using immunohistochemistry (25). However, the
expression of p53 as revealed by immunohistochemistry might
not indicate that the p53 is necessarily mutated and non-func-
tional. 
Cancer growth and progression is generally regarded as
dependent on a high rate of cell proliferation rate and a low
rate of apoptosis rate (17). Apoptosis and cell cycle arrest may
be reduced when p53 is mutated, allowing cancer growth
and progression (18, 19, 25). In this study, the relationship
between status of p53 expression and Ki-67 LI was not sta-
tistically significant. This result may indicate that p53 muta-
tion is predominantly associated with apoptosis, but not cell
proliferation. Previous studies reported similar or contrary
results (26, 27). The role of p53 mutation in tumor cell pro-
liferation has yet been controversial. Combined analysis of
p53 and COX-2 status showed that the mean Ki-67 LI value
of both positive tumors was significantly higher than that
of both negative tumors. This result suggests that molecular
and biologic factors including tumor suppressor gene may
act in the control of tumor cell proliferation.
The third aim of this study was to examine the expression
of COX-2, p53, and Ki-67 in gastric cancer and their rela-
tionship with clinicopathological characteristics including
patient prognosis. In this study, expression of COX-2 corre-
lated significantly with depth of tumor invasion. However,
there was no association between COX-2 expression and sur-
vival. There was some agreement, but also several differences
between these results and other studies (8, 28, 29). We pre-
viously reported that COX-2 expression is associated with
well differentiated and intestinal type pathway in gastric car-
cinogenesis and not useful for establishing prognoses for gas-
tric cancer (8). It is well known that well differentiated and
intestinal-type gastric cancer, which less invade and metas-
tasize, are associated with a better prognosis than poorly dif-
ferentiated and diffuse type cancer. Therefore, the prognostic
significance of COX-2 is not established in gastric cancer.
Also, expression of p53 correlated significantly with depth
of tumor invasion. However, there was no association between
p53 expression and survivial. Although relationship between
p53 expression and poorer prognosis is suggested, it is still
unclear whether p53 is an independent prognostic factor. Un-
derstanding of the molecular and biochemical mechanisms
responsible for mutation of p53 is necessary before change of
this molecule can be applied in clinical practice as a prognos-
tic factor. The Ki-67 LI, an estabilished cell proliferation mar-
ker, often correlated to prognosis in gastric cancer (30, 31).
However, in this study, when a mean Ki-67 LI value was cho-
sen as the cut-off point for discrimination of the study patients
into two subgroups as high Ki-67 LI and low Ki-67 LI, there
was no significant difference in various clinicopathological
variables including survival between the two subgroups. Liu
et al. and Kanai et al. reported that the Ki-67 LI did not in-
fluence the prognosis in gastric cancer (32, 33). These con-
troversial results may be related to the different score systems
and different antibodies used. And because tumor growth
and progression result from the imbalance between cell pro-
liferation and apoptosis, alterations in the control of apopto-
sis can be as important as those of cell proliferation. 
In conclusion, COX-2 expression is associated with tumor
cell proliferation of gastric cancer. However, tumor cell pro-
liferation through the regulation of COX-2 in gastric cancer
may not be dependent on p53 status. 
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